Filing Details
- Accession Number:
- 0000899243-22-001203
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-06 16:36:22
- Reporting Period:
- 2022-01-04
- Accepted Time:
- 2022-01-06 16:36:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1840574 | Verve Therapeutics Inc. | VERV | Pharmaceutical Preparations (2834) | 824800132 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1864112 | Sekar Kathiresan | C/O Verve Therapeutics, Inc. 500 Technology Square, Suite 901 Cambridge MA 02139 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-01-04 | 1,870 | $1.39 | 408,406 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-01-04 | 1,870 | $39.90 | 406,536 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2022-01-04 | 1,870 | $0.00 | 1,870 | $1.39 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
267,425 | 2029-04-14 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 80,997 | Indirect | Kathiresan Family 2021 Irrevocable Trust |
Common Stock | 80,997 | Indirect | Sekar Kathiresan 2021 Irrevocable Trust |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021.
- The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.